Water soluble paclitaxel derivatives
AssigneePG-TXL Company, L.P.
InventorsChun Li, Sidney Wallace, Dong-Fang Yu, David J. Yang
Life of this patent
Estimating the term…
Abstract
Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.
Claims25
A method of treating cancer in a subject comprising the steps of:
- (a) providing a composition comprising paclitaxel or docetaxel conjugated to a water soluble polyamino acids polymer having a molecular weight of at least about 5,000 D and dispersed in a pharmaceutically acceptable solution;
- (b) administering said solution to said subject in an amount effective to treat said cancer.
A method for targeting a chemotherapeutic agent into a tumor from the vasculature of a patient which method comprises:
- (A) selecting a chemotherapeutic agent selected from the group consisting of paclitaxel, docetaxel, etoposide, teniposide, camptothecin and epothilone that is covalently conjugated to a polyglutamic acid polymer, wherein said polymer has a molecular weight of at least 30,000 D;
- (B) introducing said covalently-conjugated chemotherapeutic agent conjugate to the systemic circulation of a patient with a tumor such that the polymer therapeutic agent conjugate selectively diffuses into the tumor of said patient.
A method for treating a patient having a tumor which method comprises:
- (a) selecting a chemotherapeutic agent from the group consisting of paclitaxel, docetaxel, etoposide, teniposide, camptothecin and epothilone;
- (b) covalently conjugating said agent to a polyglutamic acid polymer wherein said polymer has a molecular weight of at least about 5,000 D and wherein said conjugate is characterized by a longer circulating half-life in the systemic circulation than the unconjugated agent and the ability to accumulate in the tumor in an amount that is effective for treating the tumor;
- (c) introducing said conjugate into the systemic circulation of said patient such that the conjugate diffuses into the tumor of said patient to so treat the tumor.
Dependencies are inferred from the claim text.